This protocol applies to patients with pulmonary sarcoidosis who have dyspnea, chest X-ray findings at stage II or higher, and pulmonary function tests below the normal range — indicating moderate-to-severe pulmonary involvement that requires active treatment review.
An initial course of prednisone — aimed at improving forced vital capacity and reducing dyspnea within 1–3 months — has not achieved those goals, or corticosteroid-related toxicity has been encountered. This protocol describes the next clinical step in that setting.
When corticosteroids are insufficient or not tolerated, adding a steroid-sparing immunosuppressive agent is a recognized option. The class of agents used at this stage takes time to demonstrate a meaningful effect, and clinical response is evaluated at 6 months. The full structured regimen — including which agents are appropriate and how they are selected — is available via the link below.
For those with dyspnea, corticosteroid therapy has been shown to improve lung function for both the short term and up to five years after therapy has been discontinued.
Corticosteroids remain the initial drug of choice for treatment of parenchymal lung diseases.
If such a taper is not successful, or there is toxicity from the corticosteroids, one should consider the addition of a steroid-sparing agent, such as methotrexate or azathioprine.
Both of these agents will take up to 6 months to demonstrate effectiveness and are effective in only about two-thirds of patients.
View source ↗